CARDIAC DISEASE PREDICTION FOLLOWING  H ODGKIN LYMPHOMA: AN  EORTC  LYMPHOMA GROUP AND  GELA  FOLLOW‐UP STUDY | Zendy

Maraldo M.V. | Zendy; Giusti F. | Zendy; Kaaij M.A. | Zendy; HenryAmar M. | Zendy; Aleman B. | Zendy; Raemaekers J. | Zendy; Meijnders P. | Zendy; Moser E.C. | Zendy; KluinNelemans H.C. | Zendy; Spina M. | Zendy; Ferme C. | Zendy; Fortpied C. | Zendy; Specht L. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

CARDIAC DISEASE PREDICTION FOLLOWING H ODGKIN LYMPHOMA: AN EORTC LYMPHOMA GROUP AND GELA FOLLOW‐UP STUDY

Author(s) -

Maraldo M.V.,

Giusti F.,

Kaaij M.A.,

HenryAmar M.,

Aleman B.,

Raemaekers J.,

Meijnders P.,

Moser E.C.,

KluinNelemans H.C.,

Spina M.,

Ferme C.,

Fortpied C.,

Specht L.

Publication year - 2017

Publication title -

hematological oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.918

H-Index - 44

eISSN - 1099-1069

pISSN - 0278-0232

DOI - 10.1002/hon.2438_34

Subject(s) - medicine , hazard ratio , proportional hazards model , confidence interval , lymphoma , cumulative incidence , cohort , cancer , oncology , hodgkin lymphoma , surgery

174 CARDIAC DISEASE PREDICTION FOLLOWING HODGKIN LYMPHOMA: AN EORTC LYMPHOMA GROUP AND GELA FOLLOW‐UP STUDY M.V. Maraldo* | F. Giusti | M.A. van der Kaaij | M. Henry‐Amar | B. Aleman | J. Raemaekers | P. Meijnders | E.C. Moser | H.C. Kluin‐Nelemans | M. Spina | C. Ferme | C. Fortpied | L. Specht Department of Clinical Oncology, Rigshospitalet, Copenhagen, Denmark; Department of Statistics, EORTC Headquarters, Brussels, Belgium; Department of Internal Medicine, VU University Medical Centre, Amsterdam, Netherlands; Centre de Traitement des Données du Cancéropôle Nord‐Ouest, Centre François Baclesse, Caen, France; Department of Radiation Oncology, the Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands; Department of Radiation Oncology, Iridium Cancer Network, University of Antwerp, Antwerp, Belgium; Department of Radiation Oncology, Champalimaud Cancer Centre, Lisbon, Portugal; Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands; Division of Medical Oncology, National Cancer Institute, Aviano, Italy; Department of Hematology, Institut Gustave Roussy, Villejuif, France

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research